Table 1.
The baseline characteristics of the 45 HCC patients.
| Demographics | Experimental group (N = 25) |
Control group (N = 22) |
|---|---|---|
| Gender | ||
| Male | 20 | 18 |
| Female | 5 | 4 |
| Age | ||
| ＞65 | 12 | 10 |
| ≤ 65 | 13 | 12 |
| Comorbidities | ||
| Hepatitis B | 18 | 14 |
| Hepatitis C | 0 | 2 |
| liver cirrhosis | 14 | 10 |
| BCLC algorithm | ||
| B(intermediate) | 10 | 10 |
| C(advanced) | 15 | 12 |
| Apatinib dose | ||
| Initial dose 250 mg qd | 24 | - |
| Initial dose 125 mg qd | 1 | - |
| Duration of Apatinib treatment, (days) | 133.7 | - |
| Number of interventional therapy | 6.3(1–24) | 6.1(1–17) |
| ECOG score | ||
| 0 | 8 | 12 |
| 1 | 11 | 10 |
| 2 | 6 | 9 |